MULTIPLE INDICATION PRICING, REIMBURSEMENT AND FUNDING DYNAMICS: THE CASE OF ORPHAN INDICATIONS

被引：0
|
作者：
Wild, L. [1 ]
Forster, L. [1 ]
机构：
[1] Double Helix Consulting, London, England
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 07期
关键词：
D O I：
10.1016/j.jval.2011.08.566
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A335 / A336
页数：2
相关论文
共 50 条
  • [11] The Role of Indication-Based Pricing in Future Pricing and Reimbursement Policies: A Systematic Review
    Preckler, Victor
    Espin, Jaime
    VALUE IN HEALTH, 2022, 25 (04) : 666 - 675
  • [12] ASSESSMENT OF THE ORPHAN DRUG PRICING AND REIMBURSEMENT LANDSCAPE IN THE ASIA PACIFIC REGION
    Mukku, S. R.
    Pang, F.
    VALUE IN HEALTH, 2010, 13 (07) : A537 - A537
  • [13] EVIDENCE REQUIREMENTS FOR PRICING AND REIMBURSEMENT DECISION MAKING FOR ORPHAN DRUGS IN ASIA
    Tan, S.
    Dummett, H.
    Kirpekar, S.
    Guan, Q.
    Priest, V. L.
    VALUE IN HEALTH, 2012, 15 (07) : A621 - A622
  • [14] CHALLENGES OF FUNDING ORPHAN MEDICINAL PRODUCTS IN CANADA: QUANTIFICATION OF APPROVAL RATE AND REIMBURSEMENT
    Santosuosso, M.
    Jessa-Jablonska, M.
    Ofir, M.
    O'Neill, J.
    Gibson, M.
    Hazel, M.
    Gruenbaum, Y.
    Lipschitz, Y.
    Gurfinkel, G.
    VALUE IN HEALTH, 2022, 25 (07) : S476 - S476
  • [15] Pricing and Reimbursement Pathways of New Orphan Drugs in South Korea: A Longitudinal Comparison
    Lee, Jong Hyuk
    HEALTHCARE, 2021, 9 (03)
  • [16] Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs
    Kolasa, Katarzyna
    Zwolinski, Krzysztof M.
    Kalo, Zoltan
    Hermanowski, Tomasz
    ORPHANET JOURNAL OF RARE DISEASES, 2016, 11
  • [17] Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs
    Katarzyna Kolasa
    Krzysztof M. Zwolinski
    Zoltan Kalo
    Tomasz Hermanowski
    Orphanet Journal of Rare Diseases, 11
  • [18] Reimbursement of orphan drugs: the Pompe and Fabry case in the Netherlands
    Rinke van den Brink
    Orphanet Journal of Rare Diseases, 9 (Suppl 1)
  • [19] PAYER PERSPECTIVES ON DRUG PRICING, COVERAGE, AND REIMBURSEMENT IN OPHTHALMOLOGIC ORPHAN CONDITION IN THE UNITED STATES
    Gavaghan, M.
    Abraham, J.
    Pauer, L.
    VALUE IN HEALTH, 2013, 16 (03) : A10 - A10
  • [20] UNDERSTANDING THE PRICING AND REIMBURSEMENT (P&R) LANDSCAPE OF ORPHAN DRUGS IN EMERGING MARKETS
    Oliver, L.
    Karakusevic, A.
    Enstone, A.
    Rousseau, B.
    VALUE IN HEALTH, 2019, 22 : S860 - S861
12345